News

    El grup de IA a l'ESMO
    The PADO AI Unit presents two artificial intelligence posters at the ESMO AI & Digital Oncology Congress 2026
    20/11/2026

    The PADO Artificial Intelligence team participated in the ESMO AI & Digital Oncology Congress 2026, held in Berlin from 16 to 18 November. The congress, organised by the European Society for Medical Oncology (ESMO), brought together international experts to discuss the role of artificial intelligence in the digital transformation of oncology.

    The second edition addressed topics such as the discovery of new biomarkers and the application of language models in clinical practice. Particular attention should be drawn to the participation of Dr Víctor Moreno, Head of PADO, and his AI team, who presented two scientific posters.

    The first poster, presented by Fernando Gastón, a researcher in the group, is part of the Tangerine project and explores the use of foundation models such as CONCH and TITAN to identify biomarkers that could help predict responses to immunotherapy.

    The second poster, presented by Dr Víctor Moreno, focuses on colorectal cancer and explores the use of the UNI2 foundation model to predict survival based on pathology images. This work aims to improve the prognostic information available beyond conventional clinical and pathological criteria.

    Through this participation, PADO strengthens its international presence and contributes to the development of new applications of AI in oncology.

    El grup IA a l'ESMO

    Reunió GenRisk
    GenRisk drives precision prevention for cancer and other chronic diseases at its annual meeting in Zaragoza
    12/11/2026

    On November 4, the annual meeting of the CIBERESP strategic subprogram GenRisk was held in Zaragoza. The event featured prominent participation from the Oncology Data Analytics Program (ODAP), led by Víctor Moreno, who, as Principal Investigator (PI) of GenRisk, opened the session alongside Pablo Fernández Navarro (CNE-ISCIII), accompanied by other researchers from the group.

    During the meeting, the different teams shared the latest advances in metabolomics associated with colorectal cancer, the identification of microRNAs as molecular biomarkers, and the study of genetic susceptibility to breast cancer through mammographic density and inflammatory processes. Additionally, new analyses were presented on the interactions between genetics and lifestyle, such as the inflammatory potential of diet or alcohol consumption, based on data from the multicenter MCC-Spain study.

    Finally, the working session served to review available genetic resources, promote new publications, and strengthen ties with international consortia. Within this framework, participants discussed the progressive expansion of GenRisk toward the genetic and genomic epidemiology of other chronic diseases to continue driving precision prevention strategies.

    Taula rodona a la Jornada
    The UBOP implicated in the II Meeting of the Clinical Bioinformaticians Group of Catalonia
    5/11/2026

    The entire team of the Precision Oncology Bioinformatics Unit (UBOP), led by Dr David Cordero, attended the 2nd Meeting of the Clinical Bioinformatics Group of Catalonia, held at Hospital Clínic de Barcelona.

    The meeting brought together professionals from different hospitals to share experiences and discuss the rollout of OMIQ-HES, the results of the first clinical bioinformatics census, and the challenges surrounding the professionalisation and recognition of this discipline within the Catalan healthcare system.

    The meeting, in which the UBOP played an active role in terms of both organization and participation, also served as an opportunity to share real-world use cases, pool knowledge, and strengthen collaboration between centers.

    The event highlights the growth and consolidation of clinical bioinformatics in Catalonia, as well as the importance of collaborative work to continue advancing precision oncology.

    Taula rodona on consta David Cordero

    Imatge II Jornada Divulgativa Càncer Colorectal
    Dr Mireia Obón takes part in the 2nd Colorectal Cancer Awareness Day
    3/11/2026

    On 29 October, El Círcol de Badalona hosted the 2nd Colorectal Cancer Awareness Day, an event open to the public aimed at bringing scientific and clinical knowledge about the disease closer to the community. Organised by Amics de Can Ruti, the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Oncology (ICO) – Badalona and Germans Trias Hospital, the event focused on prevention and healthy lifestyle habits, particularly physical activity and nutrition. The event was chaired by Dr Núria Mulet Margalef, medical oncologist at ICO-Badalona, and Dr Eva Martínez Balibrea, Principal Investigator at ICO-Badalona and IGTP. Dr Mireia Obón Santacana, researcher and coordinator of the Bioinformatics and Susceptibility Unit (UBS) at PADO, also took part in a round-table discussion on the role of lifestyle habits in disease prevention, patient support and treatment.

    Imatge taula rodona Jornada Divulgació

    Imatge de Grup (Trascan)
    Dr Víctor Moreno attends TRANSCAN-3, which holds its final symposium in Bologna
    22/10/2026

    Dr Víctor Moreno, head of PADO, presents the findings of his research within the TANGERINE project at the closing event of the third initiative of the TRANSCAN network, held in Bologna from 20 to 22 October. The symposium brings together national and regional organisations that fund cancer research across Europe, providing an opportunity to reflect on the achievements of TRANSCAN-3 and discuss future activities under its successor initiative, TRANSCAN-4, which is already underway.

    The TANGERINE project is a European scientific initiative focused on using artificial intelligence (AI) to predict patients’ responses to cancer immunotherapy, survival outcomes, and treatment-related toxicity. It uses retrospective data from thousands of patients, together with prospective patient recruitment, to validate predictive algorithms.

    The European Commission co-funds the network, while the research team’s participation has been jointly co-funded by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC – TRNSC213877MORE) and the Carlos III Health Institute (ISCIII – AC22/00021).

    Imatge Trascan